Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Short Interest Update

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) was the target of a large increase in short interest in December. As of December 31st, there was short interest totaling 305,070 shares, an increase of 50.7% from the December 15th total of 202,403 shares. Based on an average daily volume of 350,979 shares, the short-interest ratio is currently 0.9 days. Approximately 2.9% of the shares of the stock are short sold. Approximately 2.9% of the shares of the stock are short sold. Based on an average daily volume of 350,979 shares, the short-interest ratio is currently 0.9 days.

Phio Pharmaceuticals Stock Performance

NASDAQ PHIO traded up $0.01 during mid-day trading on Friday, reaching $1.14. 132,139 shares of the stock were exchanged, compared to its average volume of 356,893. The stock has a market capitalization of $12.27 million, a PE ratio of -0.53 and a beta of 0.89. Phio Pharmaceuticals has a 1-year low of $0.97 and a 1-year high of $4.19. The business’s fifty day simple moving average is $1.19 and its 200 day simple moving average is $1.86.

Phio Pharmaceuticals (NASDAQ:PHIO) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.01. On average, analysts anticipate that Phio Pharmaceuticals will post -8.54 EPS for the current year.

Institutional Trading of Phio Pharmaceuticals

A hedge fund recently raised its stake in Phio Pharmaceuticals stock. Geode Capital Management LLC raised its holdings in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 38.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 57,694 shares of the company’s stock after buying an additional 16,108 shares during the quarter. Geode Capital Management LLC owned approximately 1.20% of Phio Pharmaceuticals worth $136,000 at the end of the most recent quarter. 57.31% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Wall Street Zen cut Phio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 1st. Weiss Ratings restated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Phio Pharmaceuticals has an average rating of “Hold” and a consensus price target of $14.00.

About Phio Pharmaceuticals

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.